Phathom Pharmaceuticals, Inc. (PHAT) Tops Q3 EPS by 32c, provides guidance

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q3 EPS of ($0.15), $0.32 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $49.5 million versus the consensus estimate of $47.03 million.

GUIDANCE:

Phathom Pharmaceuticals, Inc. sees FY2025 revenue of $170-175 million, versus the consensus of $170.4 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Goldman Sachs updates view on protein markets ahead of earnings